The clinical benefit of bezafibrate (BZF) in primary biliary cholangitis (PBC) has not been extensively reported in absolute measures. We assessed the number needed to treat (NNT) with BZF to prevent liver transplantation (LT) or (liver-related) death among people with PBC.
Keywords: Number Need to Treat, Primary Biliary Cholangitis, Second-line Therapy
JHEP reports : innovation in hepatology
Journal Article
English
42269833
Guideline Central and select third party use “cookies” on this website to enhance the user experience.
This technology helps us gather statistical and analytical information to optimize the relevant content for you.
The user also has the option to opt-out which may have an effect on the browsing experience.